ASTRO 2017: IAEA Trial: Safety, Efficacy of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gy each than following two 9-Gy fractions of high-dose-rate (HDR) brachytherapy, but neither overall survival nor severe treatment-related side effects differed between the treatment groups. Findings from the International Atomic Energy Agency (IAEA) trial were presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) (Abstract LBA2).
“Cervical cancer is a leading cause of cancer death among women in the developing world, and 80% of these patients live in lower- or middle-income countries, such as the ones in our trial. It is essential that we have data applicable to these real-world settings,” said May Abdel-Wahab, MD, PhD, FASTRO, a study co-author and Director of the Division of Human Health at the International Atomic Energy Agency in Vienna, Austria. “Our trial demonstrates that combining pelvic radiation therapy with four fractions of 7-Gy HDR brachytherapy is effective for locally advanced cervical cancer. In addition, it gives physicians data-supported guidance from a large, randomized study on what to expect in terms of outcomes if a regimen of two 9-Gy fractions is used in resource-constrained settings.”
Study Background
The prospective, randomized multicenter trial tested two approaches to delivering HDR brachytherapy with or without chemotherapy for patients with intermediate-stage cervical cancer. All patients received 46 Gy of curative-intent pelvic external beam radiation therapy in 23 fractions. All patients also received HDR brachytherapy in one of two dosing schedules. Half of the patients received four applications of 7 Gy each (4×7 Gy), while the other half received two applications of 9 Gy each (2×9 Gy). Additionally, half of the patients in each brachytherapy group received chemotherapy (cisplatin 40 mg/m2 in weeks 1–5), while the other half did not. The median follow-up for surviving patients was 48 months (range, 1–84 months).
A total of 601 patients with intermediate-stage cervical cancer were enrolled between September 2005 and May 2010. Patients in this international trial represented seven countries, including Mumbai (257 cases), Peru (147), South Africa (76), Brazil (53), Pakistan (31), Morocco (19), and Macedonia (18). The average patient age was 49 years (range, 26–71). All patients had either stage IIB (73.2%) or stage IIIB (26.8%) disease, and no patients had contraindications for radiation therapy or chemotherapy.
Study Findings
Overall survival at 5 years following treatment was 67.2% for all patients (95% confidence interval [CI] = 62.7%–71.2%). The survival rate was higher for women with stage IIB disease (71%) than for stage IIIB disease (58%) (P = .03). Overall survival rates for patients who received pelvic radiation and 4×7-Gy HDR brachytherapy were 73.1% and 62.2% with and without chemotherapy, respectively. Among patients in the 2×9-Gy HDR brachytherapy group, rates were 65.1% and 68.3% with and without chemotherapy, respectively (P = .1 between the four arms).
Among patients with stage IIB disease, neither brachytherapy dosing nor the addition of chemotherapy had a significant influence on the overall survival rate. Survival rates were estimated using the Kaplan-Meier method and compared between arms using the log-rank test.
Five-year rates of locoregional control favored the 4×7-Gy brachytherapy approach, with or without the addition of systemic therapy (P = .0007). Rates for patients who received pelvic radiation and 4×7-Gy brachytherapy were 88% and 89% with and without chemotherapy, respectively, compared to control rates on the 2×9-Gy brachytherapy arm of 78% and 75% with and without chemotherapy, respectively.
Severe treatment-related side effects did not differ significantly between treatment arms. Actuarial rates of grade 3 or higher genitourinary side effects for patients who received pelvic radiation and 4×7-Gy brachytherapy were 5.9% and 7.3% with and without chemotherapy, respectively; for the 2×9-Gy brachytherapy arm, they were 7.2% and 7.3% with and without chemotherapy, respectively. Actuarial rates of grade 3 or higher gastrointestinal side effects for patients who received pelvic radiation and 4×7-Gy brachytherapy were 6% and 5.3% with and without chemotherapy, respectively; for the 2×9-Gy brachytherapy arm, rates were 5.9% and 5.3% with and without chemotherapy, respectively.
There was a modest positive effect of cisplatin on toxicity in the 2×9-Gy brachytherapy arm only (P = .066), but chemotherapy did not significantly influence overall survival, cancer-specific survival, or tumor control in the cervix and surrounding region.
“The findings that chemotherapy did not significantly affect survival or tumor control in this setting seem to be different than the results of the meta-analysis from the Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration, which found 6% differences in local control due to the effect of chemotherapy,” explained Dr. Abdel-Wahab. “However, it is important to note that our study was not powered to detect differences in local control that are less than 10%. In other words, the results of the two studies are not mutually exclusive.”
In addition to providing guidance for clinical teams treating women with cervical cancer, the study also demonstrates the feasibility of conducting global clinical trials, including trials in lower- and middle-income countries where resources for research tend to be more restricted.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
